Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016020050> ?p ?o ?g. }
- W2016020050 endingPage "1625" @default.
- W2016020050 startingPage "1619" @default.
- W2016020050 abstract "Nutrient malabsorption is a negative prognostic factor in acquired immunodeficiency syndrome and recent studies have shown that pancreatic insufficiency is a codetermining factor of malabsorption.To evaluate the effectiveness of open-label oral pancreatic enzyme supplementation therapy in acquired immunodeficiency syndrome patients with fat malabsorption.Twenty-four consecutive patients with human immunodeficiency virus infection and fat malabsorption were recruited (11 males, 13 females; median age, 9.1 years). Faecal fat loss was evaluated by steatocrit assay at entry to the study (T-0), after 2 weeks (T-1) without pancreatic enzyme treatment and after a further 2 weeks (T-2) of treatment with pancreatic extracts (Creon 10 000 at a dose of 1000 units of lipase per gram of ingested dietary fat). Faecal elastase-1 and chymotrypsin were assayed at entry.Six patients (25%) had abnormally low elastase-1 and/or chymotrypsin faecal concentration. In all patients, steatocrit values were elevated at both T-0 and T-1. Five patients proved intolerant to pancreatic enzyme treatment because of the onset of abdominal pain, and therapy was discontinued. In the 19 patients who concluded the study, steatocrit values during pancreatic enzyme treatment (T-2) were significantly lower than at entry (P < 0.0001). At T-2, in eight of 19 patients, steatocrit values were within the normal limit and the frequency of cases cured or improved on pancreatic enzyme therapy (at T-2) was significantly higher than that observed during the previous study period without enzyme treatment (T-1) (P < 0.01). A positive significant correlation was found between steatocrit values at entry and the Centers for Disease Control class (P < 0.0005); also, the decrease in steatocrit values during pancreatic enzyme therapy (difference between steatocrit value at T-2 and steatocrit value at T-0) positively correlated with the Centers for Disease Control class (P < 0.05).This pilot, open-label study showed that pancreatic enzyme supplementation therapy is highly effective in reducing faecal fat loss in human immunodeficiency virus-infected patients with nutrient malabsorption. Further double-blind studies must be undertaken to verify these results and, if they are confirmed, pancreatic enzymes can be added to our weapons in the fight against human immunodeficiency virus-associated nutrient malabsorption." @default.
- W2016020050 created "2016-06-24" @default.
- W2016020050 creator A5002831988 @default.
- W2016020050 creator A5025023582 @default.
- W2016020050 creator A5029319365 @default.
- W2016020050 creator A5039192361 @default.
- W2016020050 creator A5079091053 @default.
- W2016020050 creator A5081197923 @default.
- W2016020050 creator A5082733849 @default.
- W2016020050 creator A5088747314 @default.
- W2016020050 creator A5090239706 @default.
- W2016020050 date "2001-10-02" @default.
- W2016020050 modified "2023-10-18" @default.
- W2016020050 title "Efficacy of oral pancreatic enzyme therapy for the treatment of fat malabsorption in HIV-infected patients" @default.
- W2016020050 cites W1921774856 @default.
- W2016020050 cites W1982528259 @default.
- W2016020050 cites W2043905597 @default.
- W2016020050 cites W2045446596 @default.
- W2016020050 cites W2048287313 @default.
- W2016020050 cites W2048760772 @default.
- W2016020050 cites W2069385199 @default.
- W2016020050 cites W2075987451 @default.
- W2016020050 cites W2085298509 @default.
- W2016020050 cites W2124147141 @default.
- W2016020050 cites W2132427530 @default.
- W2016020050 cites W2149852499 @default.
- W2016020050 cites W2162839974 @default.
- W2016020050 cites W2165128411 @default.
- W2016020050 cites W2922389768 @default.
- W2016020050 cites W3026032990 @default.
- W2016020050 cites W4235771279 @default.
- W2016020050 cites W4237278900 @default.
- W2016020050 doi "https://doi.org/10.1046/j.1365-2036.2001.01070.x" @default.
- W2016020050 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11564002" @default.
- W2016020050 hasPublicationYear "2001" @default.
- W2016020050 type Work @default.
- W2016020050 sameAs 2016020050 @default.
- W2016020050 citedByCount "34" @default.
- W2016020050 countsByYear W20160200502012 @default.
- W2016020050 countsByYear W20160200502013 @default.
- W2016020050 countsByYear W20160200502014 @default.
- W2016020050 countsByYear W20160200502015 @default.
- W2016020050 countsByYear W20160200502017 @default.
- W2016020050 countsByYear W20160200502018 @default.
- W2016020050 countsByYear W20160200502019 @default.
- W2016020050 countsByYear W20160200502020 @default.
- W2016020050 countsByYear W20160200502021 @default.
- W2016020050 countsByYear W20160200502023 @default.
- W2016020050 crossrefType "journal-article" @default.
- W2016020050 hasAuthorship W2016020050A5002831988 @default.
- W2016020050 hasAuthorship W2016020050A5025023582 @default.
- W2016020050 hasAuthorship W2016020050A5029319365 @default.
- W2016020050 hasAuthorship W2016020050A5039192361 @default.
- W2016020050 hasAuthorship W2016020050A5079091053 @default.
- W2016020050 hasAuthorship W2016020050A5081197923 @default.
- W2016020050 hasAuthorship W2016020050A5082733849 @default.
- W2016020050 hasAuthorship W2016020050A5088747314 @default.
- W2016020050 hasAuthorship W2016020050A5090239706 @default.
- W2016020050 hasBestOaLocation W20160200502 @default.
- W2016020050 hasConcept C126322002 @default.
- W2016020050 hasConcept C134018914 @default.
- W2016020050 hasConcept C181199279 @default.
- W2016020050 hasConcept C2775967933 @default.
- W2016020050 hasConcept C2776326425 @default.
- W2016020050 hasConcept C2777152358 @default.
- W2016020050 hasConcept C2780439177 @default.
- W2016020050 hasConcept C2781044401 @default.
- W2016020050 hasConcept C55493867 @default.
- W2016020050 hasConcept C71924100 @default.
- W2016020050 hasConcept C86803240 @default.
- W2016020050 hasConcept C90924648 @default.
- W2016020050 hasConceptScore W2016020050C126322002 @default.
- W2016020050 hasConceptScore W2016020050C134018914 @default.
- W2016020050 hasConceptScore W2016020050C181199279 @default.
- W2016020050 hasConceptScore W2016020050C2775967933 @default.
- W2016020050 hasConceptScore W2016020050C2776326425 @default.
- W2016020050 hasConceptScore W2016020050C2777152358 @default.
- W2016020050 hasConceptScore W2016020050C2780439177 @default.
- W2016020050 hasConceptScore W2016020050C2781044401 @default.
- W2016020050 hasConceptScore W2016020050C55493867 @default.
- W2016020050 hasConceptScore W2016020050C71924100 @default.
- W2016020050 hasConceptScore W2016020050C86803240 @default.
- W2016020050 hasConceptScore W2016020050C90924648 @default.
- W2016020050 hasIssue "10" @default.
- W2016020050 hasLocation W20160200501 @default.
- W2016020050 hasLocation W20160200502 @default.
- W2016020050 hasLocation W20160200503 @default.
- W2016020050 hasOpenAccess W2016020050 @default.
- W2016020050 hasPrimaryLocation W20160200501 @default.
- W2016020050 hasRelatedWork W1878458793 @default.
- W2016020050 hasRelatedWork W2014872898 @default.
- W2016020050 hasRelatedWork W2055314774 @default.
- W2016020050 hasRelatedWork W2070434797 @default.
- W2016020050 hasRelatedWork W2071171055 @default.
- W2016020050 hasRelatedWork W2079015740 @default.
- W2016020050 hasRelatedWork W2083551880 @default.
- W2016020050 hasRelatedWork W2137472202 @default.
- W2016020050 hasRelatedWork W2325451780 @default.